During the United European Gastroenterology Week 2019, held October 29-23 in Barcelona, Spain, researchers from Celltrion presented pooled data from 3 postmarketing studies of CT-P13 in patients with inflammatory bowel disease (IBD) that underscore the safety of the biosimilar.
Biosimilar infliximab CT-P13 (Remsima, Inflectra) has become established in the treatment landscape for a number of inflammatory diseases since its approval in the European Union and in the United States, and real-world evidence on the safety of the biosimilar continue to accrue.
During the United European Gastroenterology Week 2019, held October 29-23 in Barcelona, Spain, researchers from Celltrion presented pooled data from 3 postmarketing studies of CT-P13 in patients with inflammatory bowel disease (IBD) that underscore the safety of the biosimilar.
The study relied on the Pfizer CONNECT-IBD study conducted in 13 European countries, the Celltrion CT-P13 4.3 registry in 5 European countries, and the Celltrion CT-P13 KOREA PMS study in the Republic of Korea. In total, 2813 patients were included in the safety analysis. Data from these studies were collected up to the cut-off date of December 27, 2017. Given that 76.0% of the patients were in the European Union, "the results of this analysis can be considered representative of real-world [CT-P13] safety data from the EU,” write the authors.
In total, 999 of the patients had ulcerative colitis (UC) and 1814 had Crohn disease (CD). Overall, 27.43% of patients with UC and 27.78% of those with CD experienced at least 1 treatment-emergent adverse event (AE), and 10.01% and 10.92%, respectively, experienced at least 1 serious AE. A total of 8.81% and 5.68% patients in the 2 respective groups discontinued treatment due to AEs.
In terms of AEs of special interest, there were 24 cases of serious infection, including tuberculosis (TB), in the UC group and 40 cases in the CD group. Two cases of active TB were reported in the UC group and 4 were reported in the CD group. One case of serum sickness was reported in the UC group.
Three deaths occurred among the patients with UC: 1 sudden heart death, 1 case of sepsis, and 1 death due to an unknown cause. In the CD group, 1 death, attributed to rupture of aneurysm of the abdominal aorta, was reported.
The authors conclude that, among these patients with IBD, the incidence of AEs of special interest was low, and was consistent with the known safety profile of infliximab. “The pooled safety analysis,” write the authors, “suggests a favorable benefit-risk balance and safety profile for IBD patients treated with CT-P13 in EU.”
Reference
Lee SJ, Baek KM, Lee YJ, et al. A large pooled safety analysis of 3 post-marketing studies conducted in inflammatory bowel disease patients treated with biosimilar infliximab (CT-P13). Presented at: Presented at: United European Gastroenterology Week 2019; October 29-23, 2019; Barcelona, Spain.
Challenges, Obstacles, and Future Directions for Anti-TNF Biosimilars in IBD
November 9th 2024A review article on tumor necrosis factor (TNF)-α inhibitors in inflammatory bowel disease (IBD) outlined current use of anti-TNF originators and biosimilars, their efficacy and safety, the benefits and challenges of biosimilars, and the future of biosimilars in IBD.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Gastroenterology Roundup for May 2024—Podcast Edition
June 2nd 2024On this episode of Not So Different, we review the biggest gastroenterology biosimilar stories from May 2024, covering new data from conferences and journals on infliximab and adalimumab products that demonstrate positive clinical results and confirm the safety of these biosimilars, as well as the feasibility of switching to them.
Panelists Stress Stakeholder Education to Build Confidence in Biosimilars
October 31st 2024By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster trust, improve access, and ensure that biosimilars are widely accepted as high-quality, cost-effective alternatives to originator biologics.